The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
Aged
Aged, 80 and over
Carcinoma, Transitional Cell
/ diagnosis
Cystoscopy
/ methods
Female
Humans
Male
Muscle, Skeletal
/ pathology
Neoplasm Invasiveness
/ pathology
Neoplasm Recurrence, Local
/ diagnosis
Neoplasm Staging
Retrospective Studies
Risk Factors
Urinary Bladder
/ pathology
Urinary Bladder Neoplasms
/ diagnosis
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
01
2020
accepted:
28
02
2020
entrez:
24
3
2020
pubmed:
24
3
2020
medline:
26
6
2020
Statut:
epublish
Résumé
To assess the association of low- vs. guideline-recommended high-intensity cystoscopic surveillance with outcomes among patients with high-risk non-muscle invasive bladder cancer (NMIBC). A retrospective cohort study of Veterans Affairs patients diagnosed with high-risk NMIBC between 2005 and 2011 with follow-up through 2014. Patients were categorized by number of surveillance cystoscopies over two years following diagnosis: low- (1-5) vs. high-intensity (6 or more) surveillance. Propensity score adjusted regression models were used to assess the association of low-intensity cystoscopic surveillance with frequency of transurethral resections, and risk of progression to invasive disease and bladder cancer death. Among 1,542 patients, 520 (33.7%) underwent low-intensity cystoscopic surveillance. Patients undergoing low-intensity surveillance had fewer transurethral resections (37 vs. 99 per 100 person-years; p<0.001). Risk of death from bladder cancer did not differ significantly by low (cumulative incidence [CIn] 8.4% [95% CI 6.5-10.9) at 5 years) vs. high-intensity surveillance (CIn 9.1% [95% CI 7.4-11.2) at 5 years, p = 0.61). Low vs. high-intensity surveillance was not associated with increased risk of bladder cancer death among patients with Ta (CIn 5.7% vs. 8.2% at 5 years p = 0.24) or T1 disease at diagnosis (CIn 10.2% vs. 9.1% at 5 years, p = 0.58). Among patients with Ta disease, low-intensity surveillance was associated with decreased risk of progression to invasive disease (T1 or T2) or bladder cancer death (CIn 19.3% vs. 31.3% at 5 years, p = 0.002). Patients with high-risk NMIBC undergoing low- vs. high-intensity cystoscopic surveillance underwent fewer transurethral resections, but did not experience an increased risk of progression or bladder cancer death. These findings provide a strong rationale for a clinical trial to determine whether low-intensity surveillance is comparable to high-intensity surveillance for cancer control in high-risk NMIBC.
Identifiants
pubmed: 32203532
doi: 10.1371/journal.pone.0230417
pii: PONE-D-20-01946
pmc: PMC7089561
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0230417Subventions
Organisme : HSRD VA
ID : I01 HX002780
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA023108
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Urol Oncol. 2018 May;36(5):257-264
pubmed: 29395957
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
BMC Urol. 2017 Sep 6;17(1):78
pubmed: 28877694
J Urol. 2016 Oct;196(4):1021-9
pubmed: 27317986
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Cancer. 2019 Sep 15;125(18):3147-3154
pubmed: 31120559
BJU Int. 2017 Mar;119(3):371-380
pubmed: 28058776
J Natl Cancer Inst. 2003 Apr 16;95(8):588-97
pubmed: 12697851
Cancer. 2006 Apr 1;106(7):1527-35
pubmed: 16518814
J Natl Cancer Inst. 2009 Apr 15;101(8):571-80
pubmed: 19351919
Arch Intern Med. 2000 Nov 27;160(21):3252-7
pubmed: 11088086
Health Serv Res. 2016 Oct;51(5):2002-19
pubmed: 26839976
JAMA Netw Open. 2018 Sep;1(5):
pubmed: 30465041
Med Care. 2002 Aug;40(8 Suppl):IV-3-18
pubmed: 12187163
Cancer. 2011 Dec 1;117(23):5392-401
pubmed: 21780079
Can J Urol. 2016 Apr;23(2):8198-203
pubmed: 27085823
JAMA Surg. 2018 Sep 1;153(9):850-851
pubmed: 29617542
Urology. 2017 Dec;110:84-91
pubmed: 28916254